| Literature DB >> 26024316 |
Laure Frésard1, Sophie Leroux1, Pierre-François Roux2, Christophe Klopp3, Stéphane Fabre1, Diane Esquerré4, Patrice Dehais5, Anis Djari5, David Gourichon6, Sandrine Lagarrigue2, Frédérique Pitel1.
Abstract
RNA editing results in a post-transcriptional nucleotide change in the RNA sequence that creates an alternative nucleotide not present in the DNA sequence. This leads to a diversification of transcription products with potential functional consequences. Two nucleotide substitutions are mainly described in animals, from adenosine to inosine (A-to-I) and from cytidine to uridine (C-to-U). This phenomenon is described in more details in mammals, notably since the availability of next generation sequencing technologies allowing whole genome screening of RNA-DNA differences. The number of studies recording RNA editing in other vertebrates like chicken is still limited. We chose to use high throughput sequencing technologies to search for RNA editing in chicken, and to extend the knowledge of its conservation among vertebrates. We performed sequencing of RNA and DNA from 8 embryos. Being aware of common pitfalls inherent to sequence analyses that lead to false positive discovery, we stringently filtered our datasets and found fewer than 40 reliable candidates. Conservation of particular sites of RNA editing was attested by the presence of 3 edited sites previously detected in mammals. We then characterized editing levels for selected candidates in several tissues and at different time points, from 4.5 days of embryonic development to adults, and observed a clear tissue-specificity and a gradual increase of editing level with time. By characterizing the RNA editing landscape in chicken, our results highlight the extent of evolutionary conservation of this phenomenon within vertebrates, attest to its tissue and stage specificity and provide support of the absence of non A-to-I events from the chicken transcriptome.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26024316 PMCID: PMC4449034 DOI: 10.1371/journal.pone.0126776
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Number of analyzed RNA and DNA sequences in the study (after alignment to Galgal4).
|
| 141,534,451 |
|
| 65,302,559 |
|
| 1,132,275,604 |
|
| 522,420,469 |
|
| 93.1 ± 1.0 |
|
| 22.3 ± 2.1 |
|
| 16.4 ± 2.6 |
Fig 1Number of RDD candidates obtained after each filter.
RDD candidates after filtering steps.
| Chromosome | Position | DNA Nucleotide | RDD Nucleotide | Gene Name | Gene Short Name | Consequence (VEP analysis) | Number Of Edited Replicates | Mean Depth | Mean Frequency Of Edited Nucleotide |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 36367200 | A | G | ENSGALG00000027799 |
| 3_prime_UTR_variant | 2 | 25±2.83 | 0.27±0.11 |
| 1 | 74991790 | T | C | ENSGALG00000014342 |
| downstream_gene_variant, intron_variant | 7 | 27.14±9.44 | 0.38±0.1 |
| 1 | 74992334 | T | C | ENSGALG00000014342 |
| downstream_gene_variant, intron_variant | 3 | 38.33±12.34 | 0.46±0.07 |
| 1 | 74992422 | T | C | ENSGALG00000014342 |
| downstream_gene_variant, intron_variant | 3 | 30.33±6.66 | 0.3±0.06 |
| 1 | 74993229 | T | C | ENSGALG00000014342 |
| downstream_gene_variant, intron_variant | 3 | 25.33±7.51 | 0.39±0.06 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2 | 86000881 | T | C | ENSGALG00000013191 |
| upstream_gene_variant | 2 | 114.5±36.06 | 0.21±0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2 | 110994632 | A | G | - | intergenic_variant | 3 | 29.33±3.79 | 0.67±0.11 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| 3 | 38271681 | T | C | ENSGALG00000011013 |
| splice_region_variant, synonymous_variant | 2 | 40±16.97 | 0.87±0.01 |
| 4 | 17996546 | T | C | - | intergenic_variant | 3 | 24.33±7.09 | 0.27±0.04 | |
| 4 | 17999411 | T | C | ENSGALG00000009128 |
| downstream_gene_variant | 3 | 36±14.42 | 0.3±0.07 |
| 4 | 17999509 | T | C | ENSGALG00000009128 |
| downstream_gene_variant | 5 | 33±14.82 | 0.26±0.05 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 6 | 15730446 | A | G | ENSGALG00000005243 |
| intron_variant | 2 | 18.5±4.95 | 0.38±0.25 |
|
|
|
|
|
|
|
|
|
|
|
| 6 | 34848568 | A | G | ENSGALG00000010517 |
| downstream_gene_variant | 3 | 34±7 | 0.2±0.04 |
| 12 | 2800528 | T | C | ENSGALG00000003738 ENSGALG00000003799 |
| downstream_gene_variant | 3 | 29.33±10.97 | 0.55±0.19 |
| 12 | 2800601 | T | C | ENSGALG00000003738 ENSGALG00000003799 |
| downstream_gene_variant | 2 | 32.5±2.12 | 0.22±0.01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 17 | 4705 | T | C | ENSGALG00000014171 |
| intron_variant | 3 | 45±6.56 | 0.18±0.03 |
| 22 | 5274 | T | C | - | - | intergenic_variant | 2 | 16±0 | 0.7±0.18 |
| Z | 27752047 | A | G | - | - | intergenic_variant | 3 | 29±4.58 | 0.23±0.06 |
| Z | 27752050 | A | G | - | - | intergenic_variant | 3 | 28±4 | 0.84±0.05 |
| Z | 27752217 | A | G | - | - | intergenic_variant | 2 | 31±4.21 | 0.57±0.01 |
| Z | 30809802 | T | C | - | - | intergenic_variant | 2 | 23±7.1 | 0.25±0.05 |
| Z | 30815599 | T | C | ENSGALG00000005846 |
| downstream_gene_variant | 2 | 21.5±4.95 | 0.33±0.16 |
In bold, candidates tested for validation
Fig 2Proportion of base changes of RDD candidates before /after filters.
Fig 3Distribution of RDD sites in genomic features.
In silico prediction of functional consequence on edited variants.
| Variant | SIFT | PolyPhen2 | Mut. Ass. | CHASM | ProSMS |
|---|---|---|---|---|---|
| COG3 I632V | tolerated | benign | neutral | 0.40 (0.22) | could destabilize |
| CYFIP2 K320E | tolerated | benign | neutral | 0.32 (0.29) | no effect |
| GRIA2 R764G | tolerated | benign | medium | 0.17 (0.49) | no effect |
* Computed using Cravat 3.0, functional score close to 1 means functional effect (score p-value)
Fig 4Validation of candidates by Sanger sequencing (DNA) (red arrow) and pyrosequencing (cDNA) (grey).
A: Example of a canonical RDD (T-to-C) at position chr2: 86000926. The sequence is in reverse-complement. The RDD status is confirmed by pyrosequencing (A: 53%—G: 47%). B: Example of a non-canonical RDD (A-to-C) at position chr6: 29787642. The alternative nucleotide is not detected (A:100%—C: 0%).
Fig 5Editing levels observed across tissues and time.
A: 2 selected candidates (a: chr1: 167109833; b: chr13: 10717577). B: Cluster 1 candidates (a: chr13: 931843; b: chr13: 931855; c: chr13: 931888). C: Cluster 2 candidates (a: chr2: 86000926; b: chr2: 86001370). On abscissa axis: 1: Embryo stage 4.5 days—Brain, 2: Embryo stage 15 days—Brain, 3: Adult 11 monthsBrain, 4: Embryo stage 4.5 days—Heart, 5: Embryo stage 15 days—Heart, 6: Adult 11 months—Heart, 7: Embryo stage 4.5 days—Liver, 8: Embryo stage 15 days—Liver, 9: Adult 11 months—Liver.
P-values from an analysis of variance for tissue and stage effect on editing frequency.
| Chromosome | Position | Tissue effect | Stage effect | Tissue/Stage Interaction |
|---|---|---|---|---|
| 1 | 167,109,833 | 1.29E-19 | 1.63E-09 | 1.35E-07 |
| 2 | 86,000,926 | 1.63E-14 | 1.13E-21 | 4.79E-03 |
| 2 | 86,001,370 | 8.17E-05 | 2.39E-20 | 9.94E-02 |
| 13 | 10,717,577 | 2.08E-17 | 1.11E-04 | 2.32E-02 |
| 13 | 931,843 | 1.44E-16 | 1.67E-25 | 1.45E-06 |
| 13 | 931,855 | 4.02E-15 | 1.67E-17 | 0.14 |
| 13 | 931,888 | 4.57E-08 | 4.77E-24 | 0.02 |
Positions of candidates tested on multiple tissues by pyrosequencing are shown.